Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for predicting the progression and treating a chronic kidney disease in a patient

a technology of chronic kidney disease and patient, applied in the field of chronic kidney disease progression and treatment of patients, can solve problems such as pathological consequences of compensatory process

Inactive Publication Date: 2014-03-20
INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is related to a method for predicting the progress of chronic kidney disease (CKD) or monitoring CKD therapy in a patient by measuring the expression level of the NGAL gene. The invention also provides an inhibitor or antagonist of NGAL gene expression or an NGAL antagonist for preventing or treating CKD. The technical effect is to provide a novel method for predicting and monitoring CKD using a biological sample from the patient.

Problems solved by technology

However, these numbers are a small fraction of the millions of patients who are thought to have some degree of renal impairment.
Understanding the pathophysiology of CKD progression is, therefore, a key challenge for medical planning.
In some cases, this compensatory process becomes pathological with the development of renal lesions and ESRF.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example

[0090]Material & Methods

[0091]Animals:

[0092]Mice used for these studies were FVB / N, C57BL / 6 and C57BL / 6×DBA2 / F1 (B6D2F1) (Charles River), mutant jck bearing a Nek8 mutation (Jackson Laboratories), transgenic EGFR-M expressing a dominant negative isoform of EGFR under the control of kidney-specific type 1 g-glutamyl transpeptidase promoter (26) and Lcn2− / − mice (19). Lcn2− / − mice on FVB / N genetic background were obtained using a marker-assisted speed congenic strategy. Ninety-three microsatellite markers spanning each autosomal chromosome (average distance of 14.2 cM) were used to discriminate C57BL / 6 and FVB / N alleles (http: / / www.cidr.jhmi.edu / mouse). Heterozygous C57BL / 6 Lcn2+ / − mice were bred with heterozygous jck mice to obtain double-homozygous transgenic Lcn2− / − / jck mice. All experiments were performed on 9-week-old females, except for jck mice that were studied 3 weeks after birth. Animals were fed ad libitum and housed at constant ambient temperature in a 12-hour light cycle....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
blood pressureaaaaaaaaaa
concentrationaaaaaaaaaa
pharmaceutical compositionaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a method for predicting the progression of chronic kidney disease (CKD) in a patient and also to an inhibitor of NGAL gene expression or an NGAL antagonist for use in the prevention or the treatment of CKD.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a method for predicting the progression of chronic kidney disease (CKD) in a patient and also to an inhibitor of NGAL gene expression or an NGAL antagonist for use in the prevention or the treatment of CKD.BACKGROUND OF THE INVENTION[0002]Regardless of the initial insult, human chronic kidney disease (CKD) is characterized by progressive destruction of the renal parenchyma and the loss of functional nephrons which ultimately lead to end stage renal failure (ESRF). CKD represents a worldwide concern: in the USA, 102,567 patients began dialysis in 2003 (341 patients / year per / million) (1), and similar rates were found in developing countries and in particular ethnic groups (2). However, these numbers are a small fraction of the millions of patients who are thought to have some degree of renal impairment. In the United States the prevalence of chronically reduced kidney function is 11% of adults (3). Understanding the pathophy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/68G01N33/68
CPCG01N33/6893C12Q1/6883C12Q2600/118G01N2800/347G01N2800/56A61K9/0019C07K16/2803C07K2317/76C12N15/1135C12N2310/122C12N2310/14C12N2310/16C12N2310/531
Inventor TERZI, FABIOLAVIAU, AMANDINENGUYEN, CLEMENTBURTIN, MARTINEEL KAROUI, KHALIL
Owner INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com